Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Plus Capecitabine in HER2+ Breast Cancer with Brain Metastases
NCT06475443Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Henan Cancer Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06475443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475443.